Loading company…
Qnovia develops inhaled drug delivery technology, including nicotine replacement therapy for smoking cessation.
Founded in 2018, Qnovia is based in Richmond, US, and develops pharmaceutical and medical technology products. Its RespiRx™ system is a cartridge-based inhaled nicotine replacement therapy with a 12-week step-down regimen, and the company is developing delivery applications for conditions including asthma, COPD, oncology, and vaccines. It raised USD 17 million in series A funding in September 2022 and USD 14.21 million in series B funding in December 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in